Thermo Fisher Scientific Stock News

Sprawling medical device and solutions company Thermo Fisher Scientific (TMO -1.22%) wasn't looking all that healthy on Tuesday, at least as far as its stock was concerned. The company closed a pair of acquisitions, and the twin moves didn't seem to make some investors happy.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced the completion of its acquisition of Sanofi's state-of-the-art sterile fill-finish and packaging site in Ridgefield, New Jersey, marking an expansion of the companies' strategic partnership to enable additional U.S. drug product manufacturing. The terms of the deal wer...

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced the completion of its acquisition of the Purification & Filtration business of Solventum (NYSE: SOLV) for approximately $4.0 billion in cash. With the transaction complete, the business, which is now Thermo Fisher's Filtration and Separation business...

Accelerates Solventum's business transformation to deliver long-term shareholder value Net proceeds will be used primarily to pay down debt ST. PAUL, Minn.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that Marc N. Casper, chairman, president and chief executive officer, will participate in a fireside chat hosted by J.P. Morgan on Friday, September 5th, at 1:00 p.m. (ET). The live webcast of the fireside chat can be accessed via the Investors section of our website, www.t...

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, is proud to receive three R&D 100 Awards for innovations designed to advance scientific discovery in critical areas like precision medicine and cell and gene therapy research and development. All three awarded products were recognized in the Analytical/Test category, which highlights breakthroug...

mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery challenges and limited efficacy for cancer and infectious diseases, make mRNA-focused biotechs unattractive compared to broader biotech opportunities. Investors seeking exposure should consider 'pic...

MIAMI--(BUSINESS WIRE)--ERMA Systems, the AI-powered SaaS company transforming how Life Sciences organizations manage their Promotional and Medical Review Committee (PRC/MRC) processes, proudly announces the appointment of Israel Aker, PharmD, RPh, to its Advisory Board. A seasoned expert in Medical Affairs with deep experience at leading biopharmaceutical organizations, Dr. Aker brings invalua...